Active Biotech AB (publ) (STO:ACTI)
Sweden
· Delayed Price · Currency is SEK 0.0852
-0.0018 (-2.07%)
Apr 28, 2025, 10:00 AM CET
Active Biotech AB Company Description
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden.
It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors.
The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Active Biotech AB (publ)
| Country | Sweden |
| Founded | 1983 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Helen Tuvesson |
Contact Details
Address: ScheelevAegen 22 Lund, 223 63 Sweden | |
| Phone | 46 46 19 20 00 |
| Website | activebiotech.com |
Stock Details
| Ticker Symbol | ACTI |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0001137985 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Helen Tuvesson Ph.D. | President and Chief Executive Officer |
| Hans Kolam | Chief Financial Officer |
| Dr. Erik Vahtola M.D., Ph.D. | Chief Medical Officer |